124 related articles for article (PubMed ID: 38045265)
1. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
[TBL] [Abstract][Full Text] [Related]
2. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development.
Li WJ; Liu X; Dougherty EM; Tang DG
Cancers (Basel); 2022 Sep; 14(18):. PubMed ID: 36139695
[TBL] [Abstract][Full Text] [Related]
4. Selective targeting of chemically modified miR-34a to prostate cancer using a small molecule ligand and an endosomal escape agent.
Abdelaal AM; Sohal IS; Iyer SG; Sudarshan K; Orellana EA; Ozcan KE; Dos Santos AP; Low PS; Kasinski AL
Mol Ther Nucleic Acids; 2024 Jun; 35(2):102193. PubMed ID: 38745855
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness.
Kashat M; Azzouz L; Sarkar SH; Kong D; Li Y; Sarkar FH
Am J Transl Res; 2012; 4(4):432-42. PubMed ID: 23145211
[TBL] [Abstract][Full Text] [Related]
6. Chitosan nanoparticle-mediated delivery of miRNA-34a decreases prostate tumor growth in the bone and its expression induces non-canonical autophagy.
Gaur S; Wen Y; Song JH; Parikh NU; Mangala LS; Blessing AM; Ivan C; Wu SY; Varkaris A; Shi Y; Lopez-Berestein G; Frigo DE; Sood AK; Gallick GE
Oncotarget; 2015 Oct; 6(30):29161-77. PubMed ID: 26313360
[TBL] [Abstract][Full Text] [Related]
7. rAAV-based and intraprostatically delivered miR-34a therapeutics for efficient inhibition of prostate cancer progression.
Ai J; Li J; Su Q; Ma H; He R; Wei Q; Li H; Gao G
Gene Ther; 2022 Aug; 29(7-8):418-424. PubMed ID: 34226687
[TBL] [Abstract][Full Text] [Related]
8. miR-27b and miR-34a enhance docetaxel sensitivity of prostate cancer cells through inhibiting epithelial-to-mesenchymal transition by targeting ZEB1.
Zhang G; Tian X; Li Y; Wang Z; Li X; Zhu C
Biomed Pharmacother; 2018 Jan; 97():736-744. PubMed ID: 29102917
[TBL] [Abstract][Full Text] [Related]
9. Bone targeted miRNA delivery system for miR-34a with enhanced anti-tumor efficacy to bone-associated metastatic breast cancer.
Han TY; Hou LS; Li JX; Huan ML; Zhou SY; Zhang BL
Int J Pharm; 2023 Mar; 635():122755. PubMed ID: 36801480
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle Delivery of miR-34a Eradicates Long-term-cultured Breast Cancer Stem Cells via Targeting C22ORF28 Directly.
Lin X; Chen W; Wei F; Zhou BP; Hung MC; Xie X
Theranostics; 2017; 7(19):4805-4824. PubMed ID: 29187905
[No Abstract] [Full Text] [Related]
11. Erratum: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr W; Menon M; Sarkar F
Am J Transl Res; 2013; 6(1):102-103. PubMed ID: 24349627
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.
Kong D; Heath E; Chen W; Cher M; Powell I; Heilbrun L; Li Y; Ali S; Sethi S; Hassan O; Hwang C; Gupta N; Chitale D; Sakr WA; Menon M; Sarkar FH
Am J Transl Res; 2012; 4(1):14-23. PubMed ID: 22347519
[TBL] [Abstract][Full Text] [Related]
13. LncRNA NEAT1 promotes docetaxel resistance in prostate cancer by regulating ACSL4 via sponging miR-34a-5p and miR-204-5p.
Jiang X; Guo S; Zhang Y; Zhao Y; Li X; Jia Y; Xu Y; Ma B
Cell Signal; 2020 Jan; 65():109422. PubMed ID: 31672604
[TBL] [Abstract][Full Text] [Related]
14. A first-in-class fully modified version of miR-34a with outstanding stability, activity, and anti-tumor efficacy.
Abdelaal AM; Sohal IS; Iyer S; Sudarshan K; Kothandaraman H; Lanman NA; Low PS; Kasinski AL
Oncogene; 2023 Sep; 42(40):2985-2999. PubMed ID: 37666938
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-mRNA Regulatory Network Mediates Activation of mTOR and VEGF Signaling in African American Prostate Cancer.
Gujrati H; Ha S; Mohamed A; Wang BD
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328346
[TBL] [Abstract][Full Text] [Related]
16. UTMD promoted local delivery of miR-34a-mimic for ovarian cancer therapy.
Li Y; Du M; Fang J; Zhou J; Chen Z
Drug Deliv; 2021 Dec; 28(1):1616-1625. PubMed ID: 34319204
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic.
Li WJ; Wang Y; Liu R; Kasinski AL; Shen H; Slack FJ; Tang DG
Front Cell Dev Biol; 2021; 9():640587. PubMed ID: 33763422
[TBL] [Abstract][Full Text] [Related]
18. Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma.
Khan MB; Ruggieri R; Jamil E; Tran NL; Gonzalez C; Mugridge N; Gao S; MacDiarmid J; Brahmbhatt H; Sarkaria JN; Boockvar J; Symons M
Mol Med; 2021 Mar; 27(1):28. PubMed ID: 33765907
[TBL] [Abstract][Full Text] [Related]
19. LINC01006 facilitates cell proliferation, migration and invasion in prostate cancer through targeting miR-34a-5p to up-regulate DAAM1.
Ma E; Wang Q; Li J; Zhang X; Guo Z; Yang X
Cancer Cell Int; 2020; 20():515. PubMed ID: 33088221
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-34a Attenuates Paclitaxel Resistance in Prostate Cancer Cells via Direct Suppression of JAG1/Notch1 Axis.
Liu X; Luo X; Wu Y; Xia D; Chen W; Fang Z; Deng J; Hao Y; Yang X; Zhang T; Zhou L; Wu Y; Wang Q; Xu J; Hu X; Li L
Cell Physiol Biochem; 2018; 50(1):261-276. PubMed ID: 30282072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
